...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >miR-135b-and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors
【24h】

miR-135b-and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors

机译:miR-135b-and miR-146b依赖性沉默在结肠直肠肿瘤中的钙传感受体表达的沉默

获取原文
获取原文并翻译 | 示例

摘要

Studies have shown that the calcium-sensing receptor (CaSR) mediates the antitumorigenic effects of calcium against colorectal cancer (CRC). Expression of the CaSR in colorectal tumors is often reduced. We have reported previously that silencing of CaSR in CRC is caused in part by methylation of CaSR promoter 2 and loss of histone acetylation. We investigated the impact of aberrant microRNA expression on loss of CaSR expression. A microarray study in two Caco-2 subclones (Caco2/AQ and Caco2/15) that have similar genetic background, but different CaSR expression levels (Caco2/AQ expressing more CaSR than Caco2/15), identified 22 differentially expressed microRNAs that potentially target the CaSR. We validated these results by performing gain- and loss-of-function studies with the top candidates: miR-9, miR-27a, miR-135b, and miR-146b. Modulation of miR-135b or miR-146b expression by mimicking or inhibiting their expression regulated CaSR protein levels in two different colon cancer cell lines: Caco2/AQ (moderate endogenous CaSR expression) and HT29 (low endogenous CaSR levels). Inhibition of miR-135b and miR-146b expression led to high CaSR levels and significantly reduced proliferation. In samples of colorectal tumors we observed overexpression of miR-135b and miR-146b, and this correlated inversely with CaSR expression (miR-135b: r=-0.684, p<0.001 and miR-146b: r=-0.448, p<0.001), supporting our in vitro findings. We demonstrate that miR-135b and miR-146b target the CaSR and reduce its expression in colorectal tumors, reducing the antiproliferative and prodifferentiating actions of calcium. This provides a new approach for finding means to prevent CaSR loss, developing better treatment strategies for CRC.
机译:研究表明,钙传感受体(CASR)介导钙抗结肠直肠癌(CRC)的抗肿瘤作用。通常降低了结直肠肿瘤中Casr的表达。我们先前已经报道了CRC中CASR的沉默是部分通过Casr启动子2的甲基化和组蛋白乙酰化的丧失引起。我们调查了异常Microrna表达对Casr表达丧失的影响。在两个Caco-2亚克酮(CaCO 2 / aq和CaCO2 / 15)中的微阵列研究,其具有类似的遗传背景,但具有不同的CACR表达水平(表达比CaCO 2/15的CACO 2 / AQ),鉴定了可能靶向的22个差异表达的MicroRNA卡斯尔。我们通过使用顶部候选人进行效益和函数丧失的研究来验证这些结果:miR-9,miR-27a,miR-135b和miR-146b。通过模拟或抑制两种不同的结肠癌细胞系中的表达调节的Casr蛋白水平来调节miR-135b或miR-146b表达:CaCO 2 / aq(中等内源性Casr表达)和HT29(低内源性肠果水平)。抑制miR-135b和miR-146b表达导致高Casr水平并显着降低了增殖。在结直肠肿瘤的样品中,我们观察到MiR-135b和miR-146b的过表达,并且这种与Casr表达相反(miR-135b:r = -0.684,p <0.001和miR-146b:r = -0.448,p <0.001 ),支持我们的体外发现。我们证明miR-135b和miR-146b靶向CASR并降低结直肠肿瘤中的表达,降低钙的抗增殖和生产作用。这提供了一种寻找方法来防止CARR损失的新方法,开发CRC的更好处理策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号